[HTML][HTML] Treatment of acromegaly with the growth hormone–receptor antagonist pegvisomant
PJ Trainer, WM Drake, L Katznelson… - … England Journal of …, 2000 - Mass Medical Soc
Background Patients with acromegaly are treated with surgery, radiation therapy, and drugs
to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have …
to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have …
Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss
…, M Holder-Espinasse, SP Robertson, WM Drake… - Nature …, 2011 - nature.com
We used an exome-sequencing strategy and identified an allelic series of NOTCH2 mutations
in Hajdu-Cheney syndrome, an autosomal dominant multisystem disorder characterized …
in Hajdu-Cheney syndrome, an autosomal dominant multisystem disorder characterized …
[HTML][HTML] Somatic mutations of CADM1 in aldosterone-producing adenomas and gap junction-dependent regulation of aldosterone production
…, H Wachtel, PJ King, WM Drake, M Gurnell… - Nature …, 2023 - nature.com
Aldosterone-producing adenomas (APAs) are the commonest curable cause of hypertension.
Most have gain-of-function somatic mutations of ion channels or transporters. Herein we …
Most have gain-of-function somatic mutations of ion channels or transporters. Herein we …
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant
…, P Burman, DR Clemmons, WM Drake… - The Journal of …, 2005 - academic.oup.com
Context: In clinical practice, patients with acromegaly may be switched from therapy with
long-acting somatostatin analogs to pegvisomant. The effect of changing therapies on glucose …
long-acting somatostatin analogs to pegvisomant. The effect of changing therapies on glucose …
Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study
…, I Sabin, SA Akker, SL Chew, WM Drake… - European journal of …, 2013 - academic.oup.com
Objective To investigate the early and late outcomes of patients with Cushing's disease (CD)
submitted to a neurosurgical procedure as first-line treatment. Design In this single-centre …
submitted to a neurosurgical procedure as first-line treatment. Design In this single-centre …
Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients
A Agha, D Walker, L Perry, WM Drake… - Clinical …, 2007 - Wiley Online Library
Background The effect of GH replacement on thyroid function in hypopituitary patients has
hitherto been studied in small groups of children and adults with conflicting results. Objective …
hitherto been studied in small groups of children and adults with conflicting results. Objective …
Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort
…, SM Webb, A Aulinas, WM Drake… - The Journal of …, 2015 - academic.oup.com
Context: Pituitary adenomas and pheochromocytomas/paragangliomas (pheo/PGL) can occur
in the same patient or in the same family. Coexistence of the two diseases could be due to …
in the same patient or in the same family. Coexistence of the two diseases could be due to …
[HTML][HTML] [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial
…, JK Cruickshank, H Cheow, M Gurnell, WM Drake… - Nature Medicine, 2023 - nature.com
Primary aldosteronism (PA) due to a unilateral aldosterone-producing adenoma is a
common cause of hypertension. This can be cured, or greatly improved, by adrenal surgery. …
common cause of hypertension. This can be cured, or greatly improved, by adrenal surgery. …
Optimizing GH therapy in adults and children
WM Drake, SJ Howell, JP Monson… - Endocrine …, 2001 - academic.oup.com
Until the advent of modern neuroradiological imaging techniques in 1989, a diagnosis of
GH deficiency in adults carried little significance other than as a marker of hypothalamo-…
GH deficiency in adults carried little significance other than as a marker of hypothalamo-…
Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause
Most aldosterone-producing adenomas (APAs) have gain-of-function somatic mutations of
ion channels or transporters. However, their frequency in aldosterone-producing cell clusters …
ion channels or transporters. However, their frequency in aldosterone-producing cell clusters …